+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Short Bowel Syndrome Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook

  • ID: 5130030
  • Report
  • July 2020
  • Region: Global
  • 72 pages
  • VPA Research

FEATURED COMPANIES

  • Adocia SAS
  • enGene Inc
  • Genexine Inc
  • Micelle BioPharma Inc
  • Naia Ltd
  • OPKO Health Inc
  • MORE
2020 Short Bowel Syndrome PIPELINE HIGHLIGHTS

Short Bowel Syndrome is one of the widely researched conditions during 2020 with 12 companies actively focusing on realizing pipeline’s potential. Development of Short Bowel Syndrome medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Short Bowel Syndrome market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Short Bowel Syndrome.

Good progress is anticipated during 2020 and 2021 with Short Bowel Syndrome pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Short Bowel Syndrome pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.

Short Bowel Syndrome DRUG DEVELOPMENT PIPELINE OVERVIEW

The “Short Bowel Syndrome pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Short Bowel Syndrome pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Short Bowel Syndrome presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Short Bowel Syndrome pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.

Short Bowel Syndrome DRUG PROFILES

Short Bowel Syndrome development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided:
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators
Short Bowel Syndrome COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Short Bowel Syndrome drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Short Bowel Syndrome. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 12 Short Bowel Syndrome companies including company overview, key snapshot, contact information, and their strategies on accelerating Short Bowel Syndrome pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Adocia SAS, enGene Inc, Genexine Inc, Hanmi Pharmaceuticals Co Ltd, Micelle BioPharma Inc, Naia Ltd, OPKO Health Inc, Pfizer Inc, PhaseBio Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, VectivBio AG, Zealand Pharma AS

Reasons to Buy
  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Short Bowel Syndrome
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Adocia SAS
  • enGene Inc
  • Genexine Inc
  • Micelle BioPharma Inc
  • Naia Ltd
  • OPKO Health Inc
  • MORE
1. Introduction to Short Bowel Syndrome
1.1 Short Bowel Syndrome- Disease overview
1.2 Short Bowel Syndrome- Market Size
1.3 Short Bowel Syndrome- Companies Involved

2. Short Bowel Syndrome Pipeline Snapshot- 2020
2.1 Short Bowel Syndrome Pipeline by Phase
2.2 Short Bowel Syndrome Pipeline by Mechanism of Action
2.3 Short Bowel Syndrome Pipeline by Route of Administration
2.4 Short Bowel Syndrome Pipeline- New Molecular Entities
2.5 Short Bowel Syndrome Pipeline- Orphan Drug Designation/ Special Designation

3. Short Bowel Syndrome Drug Profiles
3.1 Current Status
3.2 Short Bowel Syndrome Drug Snapshot
3.3 Short Bowel Syndrome Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME

4. Company wise Pipeline and Trials
4.1 Adocia SAS Short Bowel Syndrome Pipeline Insights and Clinical Trials
4.2 enGene Inc Short Bowel Syndrome Pipeline Insights and Clinical Trials
4.3 Genexine Inc Short Bowel Syndrome Pipeline Insights and Clinical Trials
4.4 Hanmi Pharmaceuticals Co Ltd Short Bowel Syndrome Pipeline Insights and Clinical Trials
4.5 Micelle BioPharma Inc Short Bowel Syndrome Pipeline Insights and Clinical Trials
4.6 Naia Ltd Short Bowel Syndrome Pipeline Insights and Clinical Trials
4.7 OPKO Health Inc Short Bowel Syndrome Pipeline Insights and Clinical Trials
4.8 Pfizer Inc Short Bowel Syndrome Pipeline Insights and Clinical Trials
4.9 PhaseBio Pharmaceuticals Inc Short Bowel Syndrome Pipeline Insights and Clinical Trials
4.10 Takeda Pharmaceutical Co Ltd Short Bowel Syndrome Pipeline Insights and Clinical Trials
4.11 VectivBio AG Short Bowel Syndrome Pipeline Insights and Clinical Trials
4.12 Zealand Pharma AS Short Bowel Syndrome Pipeline Insights and Clinical Trials

5. Short Bowel Syndrome Market News and Updates

6. Appendix
6.1 Sources and Methodology
6.2 Contact Information
Note: Product cover images may vary from those shown
  • Adocia SAS
  • enGene Inc
  • Genexine Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Micelle BioPharma Inc
  • Naia Ltd
  • OPKO Health Inc
  • Pfizer Inc
  • PhaseBio Pharmaceuticals Inc
  • Takeda Pharmaceutical Co Ltd
  • VectivBio AG
  • Zealand Pharma AS
Note: Product cover images may vary from those shown
Adroll
adroll